Cue Biopharma (CUE) Net Cash Flow (2017 - 2025)
Cue Biopharma (CUE) posted Net Cash Flow of $15.4 million for Q4 2025, up 197.75% sequentially from -$15.8 million in Q3 2025, and up 254.96% YoY from $4.3 million in Q4 2024.
Cue Biopharma (CUE) Net Cash Flow (2017 - 2025) Analysis & Trends
Cue Biopharma has reported Net Cash Flow for 9 years, with the latest figure at $15.4 million in Q4 2025.
- Quarterly Net Cash Flow rose 254.96% year-over-year to $15.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $4.7 million (up 117.96% YoY) and the FY2025 annual result came in at $4.7 million, up 117.96% from the prior year.
- Net Cash Flow grew to $15.4 million in Q4 2025 per CUE's latest filing, from -$15.8 million in the prior quarter.
- Over five years, Net Cash Flow peaked at $21.9 million in Q4 2022 and troughed at -$36.4 million in Q3 2022.
- A 5-year average of -$2.4 million and a median of -$2.5 million in 2021 frame the typical range for Net Cash Flow.
- The sharpest annual moves came in 2022 and 2025: Net Cash Flow soared 770.93% in 2022, then tumbled 760.16% in 2025.
- Over 5 years, Net Cash Flow stood at -$3.3 million in 2021, then jumped by 770.93% to $21.9 million in 2022, then sank by 128.22% to -$6.2 million in 2023, then tumbled by 61.29% to -$10.0 million in 2024, then soared by 254.96% to $15.4 million in 2025.
- According to Business Quant data, Net Cash Flow over the past three periods registered $15.4 million, -$15.8 million, and $14.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | Cue Biopharma | 152.56 Mn | 135.14 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 15.44 Mn |
| Dec 31, 2025 | 15.44 Mn |
| Sep 30, 2025 | -15.79 Mn |
| Sep 30, 2025 | -15.79 Mn |
| Jun 30, 2025 | 14.36 Mn |
| Jun 30, 2025 | 14.36 Mn |
| Mar 31, 2025 | -9.32 Mn |
| Mar 31, 2025 | -9.32 Mn |
| Dec 31, 2024 | -9.96 Mn |
| Dec 31, 2024 | -9.96 Mn |
| Sep 30, 2024 | 2.39 Mn |
| Sep 30, 2024 | 2.39 Mn |
| Jun 30, 2024 | -11.00 Mn |
| Jun 30, 2024 | -11.00 Mn |
| Mar 31, 2024 | -7.49 Mn |
| Mar 31, 2024 | -7.49 Mn |
| Dec 31, 2023 | -6.18 Mn |
| Dec 31, 2023 | -6.18 Mn |
| Sep 30, 2023 | 1.79 Mn |
| Sep 30, 2023 | 1.79 Mn |